- In June 2019, CellGenix expanded its cytokine production facility with a new automated filling and freeze-drying line. This expansion addresses the increasing demand for GMP-grade cytokines and supports scalable production for clinical applications in cell and gene therapy
- In April 2020, Proteintech Group, Inc. received ISO 13485 certification for its HumanKine human cell-expressed cytokines and growth factors. The certification reinforces the company’s commitment to GMP standards in cytokine production, ensuring consistent quality and safety for clinical and therapeutic use
- In October 2020, Akron Biotech announced the acquisition of Cytiva to enhance its GMP-compliant manufacturing capabilities. The integration of Cytiva’s FlexFactory system aims to improve the supply of critical materials needed for advanced therapy manufacturing, including cell and gene therapies
- In March 2024, Synthekine Inc. initiated Phase 1a/1b clinical trials for STK-012, its α/β biased IL-2 partial agonist. The trials aim to evaluate the safety and efficacy of this novel cytokine therapeutic in treating cancer and autoimmune diseases. This marks a significant step forward in the development of engineered cytokine-based therapies for immuno-oncology
- In September 2024, Scale Ready and Bio-Techne Announce Optimal Closed System Cytokine Packaged for Single Step Use in Closed System G-Rex Manufacture of CAR-T and TCR Therapies
